| Poster session 1 on Oct. 24th — from 15:45 to 16:30 |
| A |
Moderator: Akihiko IKOMA, Japan |
15:30
#761 |
Robin ROHAYEM
Effect of a skin pH reducing emollient on the skin microbiome in the context of atopic dermatitis
|
15:39
#438 |
Febu JOYQuality of Life in Adult Patients with Atopic Dermatitis in Qatar
|
15:48
#425 |
Roberto TAKAOKA
Atopic Dermatitis Patient’s Journey through the Healthcare System in Brazil
|
15:57
#538 |
Robin ROHAYEM
Topical and systemic immunomodulatory therapies and the skin microbiome in atopic dermatitis: A pilot study from the CK-Care ProRaD cohort
|
16:06
#411 |
Amina Nomtondo OUEDRAOGO
Direct medical cost of emollients in the management of atopic dermatitis in Ouagadougou
|
| B |
Moderator: |
15:30
#426 |
---
---
|
15:39
#405 |
Hye-One KIM
Analysis of Skin Microbiota and Tryptophan Metabolites in Children with Atopic Dermatitis
|
15:48
#362 |
Naoko HATTORI
Delayed blanch Phenomenon to Acetylcholine and Its Association with Sweating Function in Atopic Dermatitis: A Case Study
|
15:57
#465 |
Bérénice DEGBOE
Atopic dermatitis in adults : clinical forms and associated comorbidities from 2019-2023 in the University Clinic of Dermatology-Venerology of NUHC-HKM, Cotonou (Benin)
|
16:06
#534 |
William Wael JEBRIL
Individuals with Darier disease have an increased risk of suicide and self-injurious behaviours
|
| C |
Moderator: Dirk JAN HIJNEN, Netherlands |
15:30
#392 |
Young Bok LEE
Transcriptomic Insights into Prurigo Nodularis: Unraveling Neuronal Profiles and Immune Response
|
15:39
#490 |
Alain TAÏEB
Moisturizers for Atopic Dermatitis (AD): the ISAD-WHO application to include registered creams in the core list of the essential medicines’ lists (EML and EMLc).
|
15:48
#400 |
Jiehyun JEON
Disease Modification of Methotrexate in Atopic Dermatitis with Decreasing Eosinophils and Specific Immunoglobulin E - Pilot Study
|
15:57
#368 |
Chang Ook PARK
The Future of Atopic Dermatitis Care: Defining Endophenotypes and Exploring Biomarkers for precision medicine
|
16:06
#415 |
Mohammed Nasser AL-ABDULLA
Successful treatment of Prurigo Nodularis in a Pediatric Patient using anti-Il-4 receptor-A antibody Dupilumab
|
| D |
Moderator: Medhat ASKAR, Qatar |
15:30
#395 |
Celestin Kouadio AHOGO
Atopy School: First experience in French-speaking Sub-Saharan Africa, Acquisitions, challenges and outlook
|
15:39
#369 |
Yu Ri WOO
Differential expression of antimicrobial peptides in scalp dermatitis among patients with atopic dermatitis
|
15:48
#559 |
Abdul Mannan MUSTAFA
Knowledge, attitude and practices of Primary healthcare providers reagarding Atopic Dermatitis in Multan, Pakistan
|
15:57
#366 |
Sailan WANG
Investigating the role of the FLG2 gene in Atopic Dermatitis in the Swedish population
|
16:06
#452 |
Ga-Young LEE
The Correlation between EASI Score and Multiple Allergen Simultaneous Test (MAST) Results in Atopic Dermatitis Patients
|
| E |
Moderator: Majid Ali ALAM, Qatar |
15:30
#332 |
Kiran GODSE
Atopic dermatitis in Indian skin
|
15:39
#387 |
Tsiory Iarintsoa RAZAFIMAHARO
Association between atopic dermatitis and leprosy
|
15:48
#319 |
Sinu Rose MATHACHAN
The prevalence and severity of atopic dermatitis and the pattern of pediatric dermatoses: A six-month study from a multispecialty clinic in Dubai, UAE
|
15:57
#322 |
Fatimh Hussain ALMARRI
Topical Corticosteroid Phobia Among Caregivers Of Children With Atopic Dermatitis: A Cross-Sectional Study Using TOPICOP Score In Saudi Arabia
|
16:06
#357 |
Yousef DASHTI
The microbiome in inflammatory skin disorders: The Inner Workings of The Outer Surface
|
| Poster session 2 on Oct. 25th — from 09:30 to 10:00 |
| A |
Moderator: Arturo BORZUTZKY, Chile |
09:30
#402 |
Weronika ZYSK
Can we predict dupilumab treatment outcomes in adult patients with atopic dermatitis? A retrospective single-center study
|
09:39
#333 |
Delphine STAUMONT-SALLÉ
Switching from Dupilumab to Tralokinumab or JAK inhibitors in cases of ocular and/or facial adverse events: a real-life experience
|
09:48
#774 |
Martin DOSSENBACK
Lebrikizumab versus Other Systemic Monotherapies for Moderate-to-Severe Atopic Dermatitis: A Network Meta-analysis of Short-term Efficacy
|
| B |
Moderator: Akihiko IKOMA, Japan |
09:30
#399 |
Hye-One KIM
Comparison of Skin Transcriptomes from Biopsies in Prurigo Patients with and without Atopic Dermatitis
|
09:39
#446 |
Mike BASTIAN
Optimal itch response with dupilumab irrespective of EASI outcome in adult patients with moderate-to-severe AD
|
09:48
#461 |
Yoko KATAOKA
Abnormally elevated serum TARC may predict secondary ineffectiveness of systemic JAK inhibitors
|
| C |
Moderator: Sébastien BARBAROT, France |
09:30
#434 |
Fengxian LI
A topical Chinese herbal inhibits pruritus and skin inflammation via neural TRPM8 in atopic dermatitis
|
09:39
#344 |
Brad WOODIE
Compared with dupilumab non-prescribers, dupilumab prescribers practice more evidence-based guideline care: fewer prescribed days of systemic corticosteroids and more days of topical corticosteroid-sparing agents
|
09:48
#769 |
Magdalena TRZECIAK
Contact sensitization to topical medications in patients with symptoms of allergic contact dermatitis, with and without atopic dermatitis - a 10-year retrospective analysis of patch test results
|
| D |
Moderator: Georg STINGL, Austria |
09:30
#299 |
Mutong ZHAO
Upadacitinib for Refractory Pediatric Atopic Dermatitis: A Real-World Study on Effectiveness and Safety in Dupilumab Non-Responders
|
09:39
#373 |
Seong Jun SEO
Effectiveness of Non-Live Recombinant Herpes Zoster Vaccine in Reducing Herpes Simplex Virus Reactivation in Atopic Dermatitis Patients Treated with Janus Kinase Inhibitors
|
09:48
#333 |
Delphine STAUMONT-SALLÉ
Switching from Dupilumab to Tralokinumab or JAK inhibitors in cases of ocular and/or facial adverse events: a real-life experience
|
| E |
Moderator: Kiran GODSE, India |
09:30
#356 |
Yousef DASHTI
Complications of Dupilumab Therapy: A Literature Review of Side Effects and Clinical Case Report of Renal Adverse Event
|
09:39
#335 |
Andreas WOLLENBERG
Improvements in itch and sleep disturbance are maintained up to Week 48 with nemolizumab plus TCS/TCI treatment in patients with moderate-to-severe atopic dermatitis: Results from two global phase 3 pivotal studies (ARCADIA 1 and ARCADIA 2)
|
09:48
#485 |
Park SU JUNG
Is Eczema Area and Severity Index score ³23 a suitable cut-off for severe atopic dermatitis?
|
| Poster session 3 on Oct. 25th — from 15:15 to 16:00 |
| A |
Moderator: Kiran GODSE, India |
15:15
#458 |
Florine MANJARIMANANA
Treatment satisfaction of parents of children with atopic dermatitis treated with dermocorticoids
|
15:24
#462 |
Wei LI
Abrocitinib rapidly and extensively normalizes dysregulated blood transcriptome of atopic dermatitis patients
|
15:33
#PSG |
Peter SCHMID-GRENDELMEIER
Allergic contact dermatitis due to hair adhesives
|
15:42
#766 |
Gloria Elisante MASENGA
Quality of life among adult atopic dermatitis patients attending the regional dermatology training center in Northern Tanzania
|
| B |
Moderator: Majid Ali ALAM, Qatar |
15:15
#303 |
Atsushi OTSUKA
Effectiveness and Safety of Nemolizumab in Treating Atopic Dermatitis Among Japanese Patients: A Retrospective Study at a Single Center
|
15:24
#407 |
Sun Young CHOI
Ameliorative effects of escin on inflammation via Glucocorticoid Receptor in atopic dermatitis mouse model
|
15:33
#337 |
Yi Na YOON
Dupilumab Associated Head and Neck Dermatitis with Conjunctivitis: A Case Series
|
15:42
#763 |
Sang Eun LEE
Distinct transcriptomic profiles of sensory neurons in mouse model of atopic dermatitis and psoriasis: insight into the mechanism of chronic itch in atopic dermatitis and psoriasis
|
| C |
Moderator: Akihiko IKOMA, Japan |
15:15
#457 |
Ana B. ROSSI
Dupilumab Monotherapy Prevents Flares and Provides Sustained Control of Atopic Dermatitis Over 1 Year Across Various Dosing Frequencies
|
15:24
#379 |
Carsten FLOHR
Living network meta-analysis of systemic treatments for atopic dermatitis
|
15:33
#397 |
Thomas BIEBER
Maintenance of Optimal Response Over 2 Years in Patients With Atopic Dermatitis Treated With Dupilumab
|
15:42
#767 |
Arturo BORZUTZKY
Lipidomics of vernix caseosa is modified by maternal overweight/obesity and associates with development of atopic dermatitis in the offspring
|
| D |
Moderator: Alain TAÏEB, France |
15:15
#454 |
Andreas WOLLENBERG
Treatment with tralokinumab provides long-term control of head and neck atopic dermatitis
|
15:24
#439 |
Annie ZHANG
Real-World treatment outcomes of systemic treatments for moderate-to-severe atopic dermatitis in children aged less than 12 years: 4-year results from the PEDISTAD Registry
|
15:33
#422 |
Pontus Olov Allan JONSSON
Drug survival of systemic treatments for atopic dermatitis in Sweden
|
15:42
#651 |
Erere OTROFANOWEI
Clinical and biophysical parameters of patients with Atopic Dermatitis in Nigeria and correlation with disease severity
|
| E |
Moderator: Georg STINGL, Austria |
15:15
#343 |
Mahsa TAYEFI
Body weight and tryptophan/kynurenine metabolites during treatment with dupilumab
|
15:24
#405 |
Hye-One KIM
Analysis of Skin Microbiota and Tryptophan Metabolites in Children with Atopic Dermatitis
|
15:33
#325 |
Hyounchang KO
Oral cyclosporine for pediatric atopic dermatitis: A real-world experience of efficacy and safety
|
15:42
#386 |
Justyna SZCZĘCH
TADPol study: a real-world evidence on dupilumab and upadacitinib in the treatment of moderate-to-severe atopic dermatitis in Poland
|
| Poster session 4 on Oct. 26th — from 10:35 to 11:00 |
| A |
Moderator: Kiran GODSE, India |
10:35
#430 |
Jensen YEUNG
Clinical adverse events with upadacitinib in adolescent and adult patients with atopic dermatitis: interim analysis of a real-world multicentre retrospective review
|
10:44
#355 |
Mike BASTIAN
Understanding the Patient’s Perception: Which EASI Threshold is Clinically Meaningful to Patients With Atopic Dermatitis?
|
10:53
#441 |
Annie ZHANG
Growth Analysis at Baseline in Children and Adolescents With Moderate-to-Severe Atopic Dermatitis Enrolled in Phase 3 Dupilumab Trials
|
| B |
Moderator: Georg STINGL, Austria |
10:35
#432 |
Neal KOLLER
Itch Reduction and Quality of Life Improvement in AD for First Human Use of Zabalfin
|
10:44
#762 |
Erere OTROFANOWEI
Sensitization to mites and cockroaches is highly predominant in atopic dermatitis patients in Nigeria - a pilot study from Lagos
|
10:53
#364 |
Eung Ho CHOI
Analysis of Patch Test Results Focusing on Atopic History in Rosacea Patients: A Retrospective Study
|
| C |
Moderator: Majid Ali ALAM, Qatar |
10:35
#367 |
Chia-Yu CHU
Disease burden and treatment preference for moderate-to-severe atopic dermatitis in Taiwan: a discrete-choice experiment
|
10:44
#428 |
Roberto TAKAOKA
Creating a Model for Evaluating Healthcare Disparities in the Accessibility of Treatments for Atopic Dermatitis
|
10:53
#380 |
Ana B. ROSSI
Dupilumab Improves Quality of Life in Patients With Atopic Hand and/or Foot Dermatitis
|
| D |
Moderator: Akihiko IKOMA, Japan |
10:35
#371 |
Byeol HAN
Real-world Prevalence and Associated Factors of Nipple Eczema in Patients with Atopic Dermatitis
|
10:44
#436 |
Annie ZHANG
Impact of Dupilumab Treatment on Seasonal Disease Severity in Adults With Moderate-to-Severe Atopic Dermatitis
|
10:53
#427 |
Amina Nomtondo OUEDRAOGO
Knowledge attitudes practices of atopic patients in Ouagadougou
|
| E |
Moderator: Fang WANG, China |
10:35
#378 |
Carsten FLOHR
The Global Atopic Dermatitis Atlas: A Systematic Review Mapping Global Burden of Atopic Dermatitis
|
10:44
#414 |
John C. SU
Identifying risk factors related to social disadvantage in atopic dermatitis patients who are referred to an Australian paediatric tertiary referral centre
|
10:53
#365 |
Dong hun LEE
Early-life dietary factors and risk of persistent atopic dermatitis: A nationwide cohort and cross-sectional study
|
| Poster session 5 on Oct. 26th — from 15:20 to 16:00 |
| A |
Moderator: Georg STINGL, Austria |
15:20
#396 |
Annie ZHANG
Dupilumab reduces lesion severity and extent in children <12 years of age with moderate-to-severe AD: interim results from the PEDISTAD real-world registry
|
15:29
#377 |
Shin MIN-KYUNG
Classification of facial involvement in atopic dermatitis
|
15:38
#381 |
Fenohasina RAKOTONANDRASANA
Association of Tralokinumab and Adalimumab: Good tolerance and efficacy in a case of severe atopic dermatitis and juvenile idiopathic arthritis
|
15:47
#773 |
Thomas BIEBER
EASI 90 Response Sustained up to 38 Weeks After Lebrikizumab Withdrawal Despite Negligible Serum Concentrations
|
| B |
Moderator: Akihiko IKOMA, Japan |
15:20
#320 |
Shan WANG
Real-World Treatment Outcomes of Dupilumab and Baseline Health Economic Burden in Children and Adolescents with Moderate-to-Severe Atopic Dermatitis: Results from the ADOPED-STAD Study in China
|
15:29
#460 |
Wei LI
Temporal and topographical heterogeneities in clinical manifestations of atopic dermatitis revealed by a non-selective registry in China
|
15:38
#661 |
Xin Yi N
Exploring the link between Mind and Skin: understanding the neurocutaneous axis in atopic dermatitis
|
| C |
Moderator: Kiran GODSE, India |
15:20
#376 |
John CHITTOCK
Optical Coherence Tomography Differentiates Skin Atrophogenicity of Topical Anti-inflammatory Treatments in Patients With Atopic Dermatitis
|
15:29
#449 |
John C. SU
Dupilumab Efficacy and Safety up to 2 Years in Children Aged 6 Months to 5 Years With Moderate-to-Severe Atopic Dermatitis
|
15:38
#330 |
Pranvera SULEJMANI
The Global Reach of Artificial Intelligence in Atopic Dermatitis
|
| D |
Moderator: Majid Ali ALAM, Qatar |
15:20
#431 |
Vimal H. PRAJAPATI
Use of systemic Janus kinase inhibitors for pediatric atopic dermatitis: a systematic review of randomized controlled trials
|
